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Abstract:
Background: Evidence from animal studies suggests that greater 
reductions in post-stroke motor impairment can be attained with 
significantly higher doses and intensities of therapy focused on 
movement quality. These studies also indicate a dose-timing interaction, 
with more pronounced effects if high-intensity therapy is delivered in the 
acute/subacute, rather than chronic, post-stroke period. 
Objective: To compare two approaches of delivering high-intensity, high-
dose upper limb therapy in patients with subacute stroke: a novel 
exploratory neuro-animation therapy (NAT), and modified conventional 
occupational therapy (COT). 
Methods: Twenty-four patients were randomized to NAT or COT and 
underwent 30 sessions of 60 minutes time-on-task in addition to 
standard care. The primary outcome was the Fugl-Meyer Upper 
Extremity motor score (FM-UE). Secondary outcomes included: Action 
Research Arm Test (ARAT), grip strength, Stroke Impact Scale (SIS) 
hand domain, and upper-limb kinematics. Outcomes were assessed at 
baseline, and days 3, 90, and 180 post-training. Both groups were 
compared to a matched historical cohort (HC), which received only 30 
minutes of upper limb therapy per day. 
Results: There were no significant between-group differences in FM-UE 
change or any of the secondary outcomes at any timepoint. Both high-
dose groups showed greater recovery on the ARAT (7.3 ±2.9 pts, 
p=0.011), but not the FM-UE (1.4 ±2.6 pts, p =0.564) when compared 
to the HC. 
Conclusions: Two forms of high-dose intensive upper limb therapy 
produced greater activity but not impairment improvements compared 
with regular care. Neuroanimation may offer a new enjoyable, efficient 
and scalable way to deliver increased upper limb therapy.   
 
Page 1 of 72
http://mc.manuscriptcentral.com/nnr
































































Comparing a novel neuroanimation experience to conventional therapy for high-
dose intensive upper-limb training in subacute stroke: The SMARTS2 randomized 
trial 
John W. Krakauer, M.D.1,2,3, Tomoko Kitago, M.D.4,5,6; Jeff Goldsmith, Ph.D.7; Omar 
Ahmad, Ph.D.1; Promit Roy1, Joel Stein, M.D.8; Lauri Bishop, Ph.D., D.P.T.8, Kelly 
Casey, O.T.D.3, Belen Valladares, M.P.H.9,11, Michelle D. Harran5, Juan Camilo Cortés, 
M.D.1,6; Alexander Forrence1, Jing Xu, Ph.D.1; Sandra DeLuzio3, Jeremia P. Held, 
Ph.D.11, Anne Schwarz, M.Sc.11, Levke Steiner, M.D.11, Mario Widmer, Ph.D.9, Kelly 
Jordan3; Daniel Ludwig, D.P.T.3, Meghan Moore, D.P.T.3, Marlena Barbera3, Isha Vora3, 
Rachel Stockley, Ph.D.10, Pablo Celnik, M.D.3, Steven Zeiler, M.D., Ph.D.1; Meret 
Branscheidt, M.D.11, Gert Kwakkel, Ph.D.12,13, Andreas R. Luft, M.D.9,11
1Dept. of Neurology, Johns Hopkins University, Baltimore, MD, USA
2Dept. of Neuroscience, Johns Hopkins University, Baltimore, MD, USA 
3Dept. of Physical Medicine and Rehabilitation, Johns Hopkins University, Baltimore, 
USA
4Burke Neurological Institute, White Plains, NY, USA
5Dept. of Neurology, Weill Cornell Medicine, New York, NY, USA
6Dept. of Neurology, Columbia University, New York, NY, USA
7Dept. of Biostatistics, Columbia University Mailman School of Public Health, New York, 
NY, USA
8Dept. of Rehabilitation and Regenerative Medicine, Columbia University Vagelos 
College of Physicians and Surgeons, New York, USA 
9cereneo Center for Neurology and Rehabilitation, Vitznau, Switzerland
10School of Nursing, University of Central Lancashire, Preston, UK
11Division of Vascular Neurology and Neurorehabilitation, Dept. of Neurology, 
University Hospital and University of Zurich, Zurich Switzerland
12Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
13Amsterdam Rehabilitation Research Centre, Reade, Amsterdam, Netherlands
Corresponding author: 
John W. Krakauer




Abstract word count: 248
Manuscript word count: 6104
Number of figures: 3
Number of tables: 2
Page 2 of 72
http://mc.manuscriptcentral.com/nnr

































































Background: Evidence from animal studies suggests that greater reductions in post-
stroke motor impairment can be attained with significantly higher doses and intensities 
of therapy focused on movement quality. These studies also indicate a dose-timing 
interaction, with more pronounced effects if high-intensity therapy is delivered in the 
acute/subacute, rather than chronic, post-stroke period.
Objective: To compare two approaches of delivering high-intensity, high-dose upper 
limb therapy in patients with subacute stroke: a novel exploratory neuro-animation 
therapy (NAT), and modified conventional occupational therapy (COT).
Methods: Twenty-four patients were randomized to NAT or COT and underwent 30 
sessions of 60 minutes time-on-task in addition to standard care. The primary outcome 
was the Fugl-Meyer Upper Extremity motor score (FM-UE). Secondary outcomes 
included: Action Research Arm Test (ARAT), grip strength, Stroke Impact Scale (SIS) 
hand domain, and upper-limb kinematics. Outcomes were assessed at baseline, and 
days 3, 90, and 180 post-training. Both groups were compared to a matched historical 
cohort (HC), which received only 30 minutes of upper limb therapy per day. 
Results: There were no significant between-group differences in FM-UE change or any 
of the secondary outcomes at any timepoint. Both high-dose groups showed greater 
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recovery on the ARAT (7.3 ±2.9 pts, p=0.011), but not the FM-UE (1.4 ±2.6 pts, p 
=0.564) when compared to the HC. 
Conclusions: Two forms of high-dose intensive upper limb therapy produced greater 
activity but not impairment improvements compared with regular care. Neuroanimation 
may offer a new enjoyable, efficient and scalable way to deliver increased upper limb 
therapy.  
Clinicaltrials.gov registration NCT02292251
Key words: stroke, motor recovery, upper limb, neuroanimation, rehabilitation
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Current neurorehabilitation approaches in the subacute period after stroke have 
been ineffective in reducing motor impairment beyond what is expected from 
spontaneous biological recovery plus standard of care1,2. Notably, however, recent 
studies in patients with chronic stroke have shown improvements with promising effect 
sizes at both the activity and impairment levels when greatly increased intensities and 
doses of regular upper limb therapy are provided3-6.
A large number of studies in non-human primates (see [8] for extensive review), 
some going back over a century, have shown that hemiparesis caused by induced focal 
lesions in motor cortical areas and/or their descending pathways can markedly improve 
with high-intensity and high-dose training regimens that specifically focus on a return to 
normal behavior, i.e., movement quality; especially when it is initiated early (within days 
and weeks of the injury)7,8. For example, in one study, monkeys began training on day 
five post-infarct and were trained on 600 pellet retrievals a day for three to four weeks9; 
full recovery of hand function was seen. In another study, monkeys were trained on food 
wells with the specific intention that they perform a normal precision grip rather than 
either of two possible compensatory strategies10.  This amount and type of upper limb 
training emphasizing movement quality (normal, non-synergistic movement patterns) of 
the affected limb is difficult to achieve in the limited amount of time available in standard 
rehabilitation, which instead by necessity incentivizes task accomplishment via 
compensation11. Furthermore, it has been reported that patients make a total of only 
about 30 upper limb task-based repetitions during a single therapy session12 – almost 
two orders of magnitude lower than in the cited monkey studies. 
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The goals of the SMARTS2 study were the following: 1) to test the feasibility and 
efficacy of upper limb therapy focused on movement quality when provided at intensities 
and doses comparable to those given in non-human primate studies, 2) to initiate high-
intensity and high-dose therapy early (<6 weeks post-stroke), and 3) to compare the 
efficacy of a new immersive and enjoyable animated experience (neuroanimation 
therapy, NAT)13 versus time-matched conventional occupational therapy (COT). We 
chose this early time window in the hope of maximizing training benefits, given the 
extensive evidence in animal models that there is increased responsiveness to training 
in the first weeks to a month after stroke14, and that most spontaneous recovery occurs 
in the first few months after stroke in humans15.
SMARTS2 was a multicenter, single-blinded, parallel randomized controlled trial 
in subacute stroke, comparing the efficacy of neuroanimation therapy versus intensive 
conventional occupational therapy. Both types of training provided high-dose, high-
intensity, movement-quality focused therapy. NAT additionally offered a gamified, 
motivating environment in which to practice these movements, which we hypothesized 
might have enhanced efficacy over more traditional forms of therapy. The hypothesis 
was that NAT would be superior to COT at reducing impairment, as measured with the 
Fugl-Meyer Upper Extremity motor score (FM-UE), and at least as good at improving 
arm activity, measured with the Action Research Arm Test (ARAT), as we expected a 
large reduction in impairment to generalize to activity. The secondary hypothesis was 
that both forms of high-intensity and high-dose therapy would be better than standard-
of-care levels of occupational therapy because there is more time to focus on 
movement quality. 
Page 6 of 72
http://mc.manuscriptcentral.com/nnr


































































This was a multicenter, single-blinded, parallel randomized controlled trial 
comparing the efficacy of a novel exploratory neuroanimation therapy (NAT) with time-
matched conventional occupational therapy (COT) to enhance upper limb motor 
recovery after stroke. Eligible patients within six weeks post-stroke were randomized 1:1 
to either NAT or COT using a central web-based database (Research Electronic Data 
Capture, REDCap). Randomization was blocked in groups of six and stratified 
according to baseline FM-UE score of 6-20 or 21-40. The randomization sequence was 
generated by a statistician not involved in the study and concealed from all study team 
members. 
The target therapy schedule for both groups was two daily sessions separated by 
at least an hour break, five days per week for three weeks, for a total of 30 sessions. 
Deviations from this schedule were allowed as long as all therapy sessions could be 
completed within 10 weeks post-stroke. NAT and COT were matched for active therapy 
time of 60 minutes of time-on-task per session, which was tracked by the gaming 
software in the NAT group and by stopwatch in the COT group. 
Outcome assessments were performed at four timepoints: baseline (pre-training), 
and post-training day 3 (±2 days), day 90 (±10 days), and day 180 (±10 days). All 
assessments were conducted by trained evaluators who were blinded to treatment 
allocation. Patients and caregivers were coached and given a written and verbal 
reminder not to speak to the evaluator regarding the therapy type at each assessment 
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visit. The evaluators had no contact with the participants outside of the assessment 
sessions to minimize chances of unblinding.
The trial design initially included a third arm consisting of NAT with transcranial 
direct current stimulation (tDCS). Due to slow initial recruitment, the NAT + tDCS arm 
was stopped to allow for increased recruitment in the NAT and COT groups, which was 
our primary comparison of interest. The time window for enrollment post-stroke was 
also extended from five weeks to six weeks to increase the number of eligible 
participants. 
Study Participants 
Patients were recruited from the acute stroke and inpatient rehabilitation units at 
Johns Hopkins Hospital, New York Presbyterian Hospital-Columbia, cereneo Center for 
Neurology and Rehabilitation, and their affiliated institutions. Patients were eligible for 
the study if they were 21 years old or over, had an ischemic stroke (hemispheric or 
brainstem) confirmed by CT or MRI within the previous six weeks with residual arm 
weakness (FM-UE score 6-40 pts), had no history of prior stroke with associated motor 
deficits, and were able to give informed consent and understand the tasks involved. 
Exclusion criteria included: intracranial hemorrhage, botulinum toxin injection to upper 
limb since stroke, physical or neurological condition that interfered with study 
procedures or assessment of upper limb motor function, inability to sit in a chair and 
exercise for one hour at a time, participation in another upper limb rehabilitation 
intervention study, and inability to return for all study sessions. All patients gave written 
informed consent for participation in the study. The study was approved by the 
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institutional review board at each center and registered with Clinicaltrials.gov 
(NCT02292251) prior to the start of enrollment. 
Interventions
Licensed therapists underwent both in-person and video training on the study 
interventions at each site. Materials, instructions, and documentation was standardized 
across sites, and a single therapist (L.B.) supervised training sessions.   
Neuroanimation Therapy (NAT). Participants played a custom-designed 
immersive animation-based experience: I am Dolphin  (KATA, Johns Hopkins 
University) (Figure 1). 3D movements of the paretic arm controlled the movement of a 
virtual dolphin, swimming through different ocean scenes with various task goals 
including chasing and eating fish, eluding attacks, and performing jumps. Tasks were 
designed to promote movement in all planes throughout the active ranges of motion, 
and titrated based on successful completion of progressive levels of difficulty. 
Patient’s paretic arm was unweighted using the Armeo®Power (Hocoma AG, 
Volketswil, Switzerland), an upper limb exoskeleton device. This allowed practice of 
multijoint 3D arm movements despite antigravity weakness without requiring a therapist 
to actively lift the paretic arm. The degree of unweighting provided by the exoskeleton 
was adjusted for each patient to maintain shoulder flexion to 90 degrees at rest so as to 
provide weight-support of the paretic limb throughout its full active range in all 
directions. No active assistance was given along the line of movement by the device. 
The device was integrated with a custom gaming software in a room which simulated an 
immersive oceanic environment. A large screen displayed the dolphin in his 
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environment, oceanic sounds and music were played, and the lights were dimmed for 
the entirety of each session. A licensed physical or occupational therapist was present 
throughout each session and provided verbal and tactile feedback to assure high-quality 
movements (i.e. normal non-synergistic movement patterns) and exploration of the full 
workspace.
Modified conventional occupational therapy (COT). COT targeting the upper limb 
was administered by a licensed therapist according to a written standardized protocol. 
Active COT time was matched to that of the NAT group (60 minutes per session). The 
Chedoke-McMaster Stroke Assessment Stage16 for the hand and arm was administered 
at the beginning of each week to guide interventions aligned with the specified level of 
function. Therapeutic exercises consisted of range of motion (stretching) and 
strengthening exercises of the paretic arm, and training of ADLs, such as simulated 
cooking/eating, dressing, grooming and cleaning tasks. A typical COT session would 
include 30 minutes of impairment intervention (e.g. scapular stability, weight bearing, 
active range of motion, stretching, and strengthening), and 30 minutes of activity 
training (e.g. reaching, grasping, pinching, bilateral limb coordination during functional 
activities, ADLs). Therapists were given a list of activities from which to choose but 
could add additional personalized activities that targeted the specified upper limb 
movements for the session. Functional activities were broken down into their movement 
components first and then practiced through gradual progression of complexity and 
difficulty, similar to shaping strategies employed in constraint-induced movement 
therapy. Activities were trained using either the paretic or bilateral upper limb(s) as 
appropriate for successful completion of the task. The first session of the day targeted 
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shoulder/elbow, the second session targeted wrist/hand. Therapists focused on 
movement quality during the COT sessions by preventing compensatory movements 
and discouraging use of abnormal synergies. The musical soundtrack of NAT was 
played during COT to maintain blinding if the therapy was conducted in close proximity 
to blinded evaluators. 
All therapeutic activities were documented by the therapy team, including the 
amount of assistance provided (e.g. passive mobility, active assisted mobility, weight 
bearing), any modifications to the exercise, and total time spent on each area of the 
upper limb. Participants were not explicitly instructed with regard to integrating the 
activities into the home environment.  
Clinical study outcomes 
At the baseline visit, patients underwent a comprehensive clinical evaluation that 
included: medical chart and radiological review, National Institutes of Health Stroke 
Scale (NIHSS), proprioception assessment (using distal phalanx testing, abnormal 
defined as <3/5 trials incorrect), Montreal Cognitive Assessment17, Florida Apraxia 
Battery18, star cancellation test of visuospatial neglect (presence of hemineglect 
determined by cutoff score of 4419), and Beck Depression Inventory-II20. Study 
assessments were performed at four timepoints: baseline (pre-training), and post-
training days 3 (±2 days), 90 (±10 days), and 180 (±10 days). All evaluators underwent 
video and in-person training prior to conducting study assessments and were blinded to 
patients’ treatment allocation. 
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The primary outcome measure was the change in upper limb impairment 
measured by FM-UE, from baseline to post-training day 3. The FM-UE is a widely used, 
reliable, and validated measure of motor impairment in patients with stroke21. It 
evaluates the ability to make upper limb movements in and out of synergy patterns and 
consists of 33 items graded on an ordinal scale (0-2), with a best possible score of 66. 
The minimal clinically important difference (MCID) for the FM-UE is considered to be 
approximately 10% of the maximum score, or 6.6 points21.
Secondary clinical outcome measures included changes from baseline to day 3 
post-training in: 1) ARAT, an assessment of upper limb activity limitation and dexterity 
with the MCID for the paretic arm being 12 points22 2) grip strength using a Jamar 
dynamometer (average of three trials, MCID 5kg22), and 3) the hand domain of the 
Stroke Impact Scale (SIS hand) version 2.0, a self-reported measure of hand function23. 
All measures were also assessed at 90 and 180 days post-training, to evaluate longer-
term gains. Measures of therapy compliance included number of sessions completed 
and minutes of active therapy within each session. 
Kinematics of planar reaching 
Motor control of the proximal arm was evaluated using a planar arm reaching 
task and analyzed using methods that have been previously described15 (for detailed 
information, see Supplemental Materials). 
Finger strength and individuation 
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Finger strength and individuation were evaluated using an ergonomic keyboard 
device that measures isometric forces produced by each finger24 (for detailed 
information, see Supplemental Materials). 
Statistical analysis 
Each outcome measure (FM-UE, ARAT, grip strength, SIS hand, AMD2, finger 
MVF and individuation index) was analyzed using the same framework and model 
structure. Specifically, we used a linear mixed model in which timepoint was treated as 
a categorical predictor with four levels (reference: baseline visit), therapy type was a 
categorical variable with two levels (reference: NAT), and all timepoint by therapy type 
interactions were included. Additionally, a subject-specific random intercept accounted 
for within-subject correlation across timepoints. This model structure estimates the 
mean change in outcome value from baseline to each timepoint as well as the 
difference in this change over time comparing NAT to COT groups, using all available 
subject data at each visit. Regression diagnostics were used to assess model fit, and 
two-sided Wald tests were used to assess statistical significance for group-level 
comparisons. 
We conducted a power analysis for the ability to detect a difference in treatment 
effect between NAT and COT groups. This analysis was based on a two-sample t-test 
with two-sided alpha level set at 0.05 and assumed the difference between groups in 
the change in FM-UE score would be 7 (MCID). For an effect standard deviation of 5, 
10 subjects per group yields 84% power to detect the true alternative; for an effect 
standard deviation of 7, 20 subjects per group yields 87% power. We planned to 
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randomize 24 subjects in each group, based on our observed attrition rate of 20% for 
previous longitudinal stroke studies. 
Comparison to historical cohort (HC). In exploratory analyses, we sought to 
compare FM-UE and ARAT outcomes among patients in the current study, all of whom 
received an intensive intervention, to patients who received usual clinical care. To do 
so, we used data from the EXPLICIT trial25, which was conducted in the Netherlands 
and randomized patients within 14 days of first-ever hemiparetic stroke to modified 
constraint induced movement therapy or usual care. Specifically, patients in the 
EXPLICIT usual care cohort received occupational therapy based on current Dutch 
guidelines for 30 minutes a day, five days a week for three weeks beginning within five 
weeks post-stroke. This amount of therapy approximately matches the average number 
of minutes spent on therapeutic activities for the upper limb in a typical OT session in 
the United States12. Usual care patients from the EXPLICIT trial were matched to 
patients in our intense treatment groups (entire SMARTS2 cohort) based on day post-
stroke (± 4 days) and severity (± 4 points for FM-UE and ARAT). After candidate 
matches were found, we randomly sampled a single subject to serve as the match for 
each subject in the intense treatment group. In this analysis, we computed the change 
in FM-UE and ARAT between baseline and day three post-training for patients in the 
SMARTS2 group and a similar timeframe for the matched patients in the EXPLICIT 
usual care group, and compared the average change between groups. Because there 
can be several potential matches of whom one is selected, we repeated the full analysis 
and aggregated results to account for uncertainty in the matching process. 
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Between April 2015 and October 2017, 4030 patients with ischemic stroke were 
assessed for eligibility (Figure 2). The study was stopped after 24 subjects were 
randomized due to slow recruitment. Table 1 summarizes baseline characteristics of 
patients who were randomized. The median number of days from stroke onset to 
baseline assessment was 19.0 days (IQR 12.0, 33.0) and 14.0 (IQR 12.5, 35.5) in the 
NAT and COT groups, respectively. There were no significant differences in gender, 
arm affected, proportion receiving tissue plasminogen activator or mechanical 
thrombectomy, median NIHSS score, proportion with hemineglect, proportion receiving 
selective serotonin reuptake inhibitors, or baseline FM-UE or ARAT scores. The COT 
group did have statistically worse scores on the Florida Apraxia Battery, whereas the 
NAT group had worse depression scores at baseline.
One patient in the NAT group did not receive the intervention due to 
transportation issues. Two patients withdrew from the study before the end of the 
planned intervention: one preferred to receive only standard rehabilitation, and one was 
transferred to another facility. Compliance with active therapy was high in both groups. 
Excluding the 3 patients who did not receive the intervention or withdrew before the end 
of therapy, the mean total time in active therapy was 1769 minutes for NAT (98% of 
target) and 1801 for COT (100% of target). Two patients in the NAT group required 
minimal assistance from the therapist to initiate movement in the first few sessions but 
were subsequently able to complete the training on their own. Twenty-one patients 
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completed the post-training day 3 assessment (88%), 20 completed the post-training 
day 90 assessment (83%), and 19 completed the day 180 assessment (79%). 
Clinical outcomes 
Our primary outcome was the change in FM-UE score from baseline (pre-
training) to post-training day 3. There was no significant difference between NAT and 
COT groups in our primary outcome of FM-UE changes from baseline to day 3 post-
training (difference 1.34, standard error [SE] 5.15, p=0.797), or in FM-UE changes from 
baseline to day 90 (difference -3.28, SE 5.26, p=0.316) and day 180 (difference -0.09, 
SE 5.38, p=0.132) post-training (Table 2). There was similarly no significant difference 
between NAT and COT for the change in ARAT from baseline to day 3, day 90, or day 
180 post-training (Table 2). Grip strength and SIS hand also showed no between-group 
differences in change from baseline at any timepoint (Table 2). 
Reaching kinematics 
We calculated the average squared Mahalanobis distance (AMD2) for reaching 
trajectories performed with the paretic arm at the four timepoints, compared to a 
reference population of neurologically-healthy control subjects. There were 2 patients in 
the COT group whose reaching kinematic data were excluded from analysis because 
there were too few movements in the baseline session that were suitable for inclusion in 
the analysis. An additional 2 patients were missing baseline assessments of reaching 
kinematics (1 in each group) and therefore were not included in the analysis of change 
scores from baseline. Of the remaining patients, day 90 data were missing for 2 
Page 16 of 72
http://mc.manuscriptcentral.com/nnr
































































subjects and day 180 data were missing for 2 patients, due to time constraints or 
withdrawal from the study. There was improvement in reach kinematics across the 
intervention period but there was no significant difference in the change in AMD2 from 
baseline between NAT and COT groups at day 3, day 90, or day 180 post-training 
(Table 2). There was a significant correlation between the AMD2 and the ARAT (p = 
0.028) but not the FM-UE (p = 0.622).
Finger strength and individuation 
Maximum voluntary force and finger individuation index were calculated for the 
more affected arm at the four timepoints as described above. 1 patient in the NAT group 
did not complete the tasks at baseline and was excluded from analysis. There were also 
data missing for 4 patients at post-training day 90 (2 in NAT and 2 in COT), and 5 
patients at post-training day 180 (2 in NAT and 3 in COT). We found no significant 
between-group difference in the change in MVC or individuation index from baseline to 
any post-training timepoint. (Table 2). 
Comparison of intensive therapy to the historical cohort (HC)
In an exploratory analysis, we compared the change in FM-UE and ARAT from 
baseline to post-training day 3 in our SMARTS2 study cohort (NAT and COT groups 
combined) to changes across a similar timeframe with usual care in a historical cohort 
from the EXPLICIT-stroke study25. Patients in SMARTS2 were matched by time post-
stroke and severity (FM-UE and ARAT) with patients from EXPLICIT. We observed a 
significant benefit in upper limb activity (ARAT difference 7.33, SE 2.88 pts, p=0.011) 
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but not for impairment (FM-UE difference 1.44, SE 2.57, p=0.564) with the intensive 
therapy provided in SMARTS2 compared with usual care (Figure 3). 
Adverse events 
There were a total of 55 adverse events (AEs) that occurred in 13 patients during 
the study. There were 4 serious adverse events in the COT gorup that were unrelated to 
the study procedures, (2 falls resulting hospitalization and 2 unrelated medical 
conditions). Of the 51 non-serious AEs, 23 (42%) occurred in the NAT group and 32 
(58%) occurred in the COT group. In the NAT group, 5 AEs were probably related (neck 
pain, fatigue in 3 patients, and bruising) and 6 AEs were possibly related (eye pain in 2 
patients, headache, nausea, worsened ataxia, and a fall) to study procedures. In the 
COT group, two AEs were definitely related (wrist pain in 2 sessions), 1 probably related 
(pain), and two possibly related (pain, fall) to study procedures.
DISCUSSION
In this randomized, single-blinded proof-of-concept trial we sought to test the 
idea, inspired by studies in non-human primates, that high-intensity and high-dose 
upper limb therapy focused on movement quality rather than task accomplishment, and 
delivered early after stroke, would reduce motor impairment more than usual care does. 
We tested this main idea by taking two distinct approaches. The first was administering 
high doses of conventional upper limb therapy. The second was a new immersive 
animated experience that centers on a proprietary form of animation designed to 
promote playful exploration of high quality continuous 3D arm movements13. Here we 
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found that both approaches led to similar changes in the FM-UE, ARAT, reaching 
kinematics, finger strength, and finger individuation. Looking at a historical cohort, we 
found that both approaches were superior to usual care with respect to the ARAT but 
not the FM-UE. Unfortunately, hand and planar kinematic measures were not available 
for the historical cohort. 
Conventional occupational therapy (COT) mainly emphasizes repetitive task-
oriented training (TOT)26,27, an approach predicated on practice schedules based on 
motor learning principles. Not much time is dedicated to the upper limb in regular 
therapy sessions12, which means that TOT focuses more on compensatory movements 
for task accomplishment. That said, there is nothing inherent to COT that precludes a 
switch in emphasis to movement quality, especially if therapists are given more time 
with the patient, as they were in SMARTS2. In three recent studies in patients with 
chronic stroke, large gains in both the ARAT (or other activity-level measure) and the 
FM-UE were seen when patients were provided with either five or six hours of upper 
limb therapy a day for five days/week for three, six or twelve weeks3-5. Clearly these are 
very high intensities and doses of therapy. In two of the studies4,5, the authors explicitly 
state that they wanted to make “movement practice as close to normal as possible”, and 
did so by progressing from single-joint to two-joint movements, then assembling these 
into task components and finally practicing performance of the full task. It is evident that 
they combined the more traditional neurophysiological approach, which focuses on 
movement quality, with TOT. The therapists in our study took a comparable approach in 
the COT group, as outlined in the methods section. In fact, they explicitly stated on 
Page 19 of 72
http://mc.manuscriptcentral.com/nnr
































































questioning that they were able to focus on movement quality precisely because they 
had more time with the patient. 
The NAT and COT groups showed comparable changes in ARAT scores. These 
changes were significantly greater than the changes seen in the historical control group 
receiving usual care over the same time period. The ARAT is a valid and responsive 
measure of upper limb activity on the ICF scale28,29 and its components have 
considerable overlap with the reach and grasp tasks in non-human primate experiments 
investigating motor recovery. Indeed, the ARAT correlates well with kinematic measures 
of reach and grasp30. 
We argue here that the changes in the ARAT in the NAT and COT groups are an 
indication of true improvement in the quality of arm and hand motor control and not just 
compensation, even though performance on items scored less than 3 (i.e., “normal”) 
can include compensatory movements. First, we know that the ARAT can show, just like 
the FM-UE, changes, as we saw here (13.4 and 14.70 points from baseline to day 3 
post-training in NAT and COT groups, respectively), that are larger earlier compared to 
later after stroke 31. That ARAT changes are greater when high-dose therapy is given 
earlier than later means suggests that they, at least in part, reflect true restitution and 
not just learned compensation. Second, if the two intervention groups were just being 
trained to compensate better than usual care, then this must be because they learned to 
compensate during the intervention. This would not be possible for the NAT group, 
however, because there was no functional reach and grasp training. Third, large 
improvements in activity measures have been seen with intense and high dose COT in 
patients with chronic stroke5,6. These changes seem to be dose-dependent, only 
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becoming large when 90 hours or more of treatment are given3-5. In contrast, 32 hours 
does not lead to large ARAT changes31. If large ARAT changes were just due to 
optimizing compensatory strategies it seems unlikely that they would not also be seen 
after 32 hours of COT. Finally, here we found a significant correlation, as have 
others30,32, between improvement in the quality of arm kinematics and the ARAT. Thus, 
like in non-human primates8, we conclude that intense and high-dose upper limb 
therapy focused on movement quality can at least partially restore motor control in the 
upper limb in the subacute period after stroke; it does not just train compensatory 
movements. 
Notably, we did not see an increase in the FM-UE, our primary outcome 
measure, beyond what was seen in the usual care historical control group. Of course, 
as we were studying subacute rather than chronic stroke, there were large changes in 
the FM-UE due to spontaneous recovery but we were not able to augment them with 
either of our interventions. It is always possible that this is a false negative result given 
the low n, but a previous study of early intense and high-dose upper limb therapy, in this 
case constraint-induced movement therapy, also reported a dissociation between the 
ARAT and the FM-UE25. 
It is possible for ARAT improvements to reflect true changes in motor control and 
yet not be detected by the FM-UE score due to differences in emphasis for the two 
scales. For example, a patient who has regained active range of movement in the 
shoulder/elbow but has persistent difficulty with out of synergy movements (e.g., unable 
to initiate shoulder flexion or abduction without bending the elbow, which would confer a 
score of “0” on these FM-UE items) may nevertheless improve on the ARAT by gaining 
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the ability to reach the top shelf through improved shoulder flexion and elbow extension. 
Another situation in which one may see a dissociation between FM-UE and ARAT 
changes is a patient who primarily regains distal dexterity, which is weighted more 
heavily on the ARAT than the FM-UE. 
The differential responsiveness of the FM-UE and the ARAT to an intervention is 
not altogether surprising. FM-UE and ARAT measure different constructs of the ICF 
model, reflecting the levels of body function and activity, respectively. In addition, the 
FM-UE scale was primarily devised to quantify post-stroke synergies over the course of 
motor recovery 33 whereas the ARAT emphasizes assessment of prehension (combined 
reach and grasp) during more functional tasks29,34. In other words, one primarily targets 
a positive sign and the other a negative sign of the upper motor neuron syndrome8. That 
being said, synergies will intrude on a functional task, especially in the absence of arm 
weight support35,36, which is why the two measures often correlate with each other37,38. 
It is unfortunate that the FM-UE has come to be considered synonymous with overall 
impairment after stroke, even though it was designed to assess mostly a single 
component of impairment, namely synergies, over strength or dexterity. This is 
problematic because thus far it seems that the positive and negative symptoms of 
stroke respond differently to interventions in the sub-acute period. In this study, we saw 
significant improvement in ARAT but not in FM-UE with our intensive movement quality-
focused training, and a similar finding was reported when extra sessions of constraint-
induced movement therapy were added in the sub-acute period in the EXPLICIT trial25.  
The divergence of ARAT and FM-UE in comparison to usual care was descriptive rather 
than statistical, due to the challenges in performing a robust statistical comparison 
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between values of different scales, the dependence between tests of each outcome, 
and the repeated matching framework that was used to compare recovery between 
groups. It is to be hoped that new kinematic measures will soon be developed that can 
distinguish arm dexterity/quality of motor control from both synergies and compensation 
during performance of 3D functional tasks39,40. This is of utmost importance because 
hemiparesis in humans appears to be both a deficit disorder related to damage to the 
corticospinal tract41,42 and a movement disorder, perhaps related to upregulation of the 
reticulospinal tract43-45. These positive and negative signs of hemiparesis will likely need 
distinct forms of intervention. 
Our findings for the NAT and COT groups are congruent with what has been 
reported in many recent neurorehabilitation studies and trials – both the novel 
intervention group and the control group show similar, and often large, treatment 
responses. This has been taken as evidence that new technological or pharmacological 
interventions do not outperform higher intensities and doses of conventional therapy or, 
by extension, usual clinical care. In a recent review of 15 neurorehabilitation trials 
conducted in the last five years it is stated: “There is no clear evidence that 
interventions tested in large multicenter stroke rehabilitation trials are superior to current 
care. Furthermore, patients benefited from both the experimental and control 
interventions at both the subacute and chronic stages”46. The crucial point being missed 
here, however, is that control interventions in clinical trials often consist of more, and 
sometimes considerably more, conventional therapy than is usually given during regular 
clinical care. This is certainly the case in our study where patients in the COT group 
received two hours a day of therapy for five consecutive days over three weeks. 
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Because of the greatly increased time available, both NAT and COT were able to 
increase the emphasis on movement quality and discourage use of compensatory 
movements. At the very least, one can safely say that there was more movement-
quality-based training than in the historical cohort. In addition, trials tend to select for 
patients with less comorbidity and fewer cognitive deficits, which allows them to receive 
higher doses of usual care. Therefore, the positive results for controls in trials do not 
imply that usual conventional care is equally efficacious to the novel intervention. 
Indeed, trials that have directly compared higher doses with usual doses of conventional 
care have found a difference between them47-49. Thus, the fact that a new approach, like 
the NAT here, is not significantly different from high doses of COT should be taken as a 
reason for optimism. This implies that the new intervention must possess an active 
ingredient that potentially could be further optimized in terms of efficacy, efficiency, cost-
effectiveness, and scalability. This situation can be considered analogous to what 
happened in the evolution of thrombectomy for acute stroke. In 2013, three trials 
showed no benefit of thrombectomy over usual care50-52. By 2015, five trials showed 
superiority for thrombectomy53. What happened? The two main reasons were choice of 
the correct technology for clot removal and a change in protocol design.
As with post-stroke thrombolysis, it is possible that we are on the cusp of a 
change in the delivery and efficacy of upper limb neurorehabilitation. In this case, the 
correct choice would be to move toward more immersive experiences to promote 
intense exploratory training with a focus on movement quality. The protocol change 
would be, as in SMARTS2, to encourage exploratory multi-joint movements outside of a 
task context for at least two hours a day. Thus, based on the results here, we suggest 
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that an alternative to just increasing the amount of time available to administer COT, is 
to devise technology-based solutions are scalable and that make it easier and more 
enjoyable to deliver higher doses and intensities of impairment-focused therapy54. It 
should also be emphasized, that even though in this small study we found no significant 
difference between COT and NAT for delivery of higher doses of intense upper limb 
therapy, it does not need to be either/or. It may turn out that the two approaches can 
complement each other. COT could be considered analogous to drills in sport, for 
example practicing backhands in tennis for an hour. NAT could be the holistic approach 
where you combine all the components into a full game. 
Compliance with therapy was high in both NAT and COT groups, reaching 98% 
and 100% of targeted time on task, respectively. Overall both interventions were safe, 
with no serious adverse events related to study procedures. There were, however, more 
adverse events in the COT group than the NAT group. Fatigue was reported more often 
in the NAT group, which therapists did not always perceive to be a negative because 
the therapy was designed to be challenging. Other side effects in the NAT group such 
as transient headache and pain have been reported previously with game-based 
interventions and are not unexpected with high intensity training55.
This study clearly has a number of limitations. First, the number of patients in this 
proof-of-concept trial was low. Indeed, we recruited only half the number of patients we 
anticipated. This is attributable both to our inclusion/exclusion criteria and the 
challenges of providing two hours of time-on-task upper limb therapy, five days a week 
beginning in the first six weeks after stroke in addition to usual care56,57. Furthermore, 
incorporation of mechanical thrombectomy as standard of care led to fewer patients with 
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severe to moderate motor deficits. Second, we were only able to begin our interventions 
after patients were discharged from in-patient acute rehabilitation at the sites in the 
United States due to the challenges of delivering high doses of therapy in addition to 
standard care in the inpatient rehabilitation setting as well as the need for short length of 
stay58; the average start time was therefore about three weeks post-stroke. From our 
previous work, we have shown that the time window of heightened neuroplasticity 
responsible for spontaneous recovery, and perhaps for enhanced training-related 
improvement that takes advantage of this heightened neuroplasticity, might be as short 
as 5 weeks15. This difficulty with our enrollment time window attests to the continuing 
challenge of conducting neurorehabilitation trials in this early time period after 
stroke46,58,59. Third, we did not track amount of upper limb activity at home during this 
study, thus are unable to quantify whether either of the training interventions influenced 
amount of limb use in the real world. Fourth, we had to use a historical usual care 
group, albeit an extensive and well-matched one25. This was necessary because we 
were not able to ask patients to enroll in a trial offering three weeks of extra care with 
the chance that they would end up in the control group that got no extra therapy but 
would nevertheless require them to make trips to the hospital for assessment. Given our 
strict time window offering the active intervention later was not an option. Another point, 
as we made above, is that in clinical trials, the control intervention is most often not 
“usual” care but an amplified and often unrealistic version of it46. Here we were fortunate 
that a cohort existed that delivered care of the upper limb that was close to what 
patients actually receive in the subacute post-stroke period. 
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Increasing the dose and intensity of upper limb rehabilitation training early after 
stroke, with focus on movement quality, led to gains beyond those seen with usual care. 
This additional improvement was achieved either by having therapists provide much 
more COT or with a novel exploratory animation-based approach with exoskeletal 
weight support. This is exciting, as it suggests that an immersive animation-based 
experience combined with weight-support might pave the way forward for providing high 
doses of upper limb rehabilitation focused on movement quality in a more efficient, 
enjoyable, and scalable way at any time post-stroke. 
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Background: Evidence from animal studies suggests that greater reductions in post-
stroke motor impairment can be attained with significantly higher doses and intensities 
of therapy focused on movement quality. These studies also indicate a dose-timing 
interaction, with more pronounced effects if high-intensity therapy is delivered in the 
acute/subacute, rather than chronic, post-stroke period.
Objective: To compare two approaches of delivering high-intensity, high-dose upper 
limb therapy in patients with subacute stroke: a novel exploratory neuro-animation 
therapy (NAT), and modified conventional occupational therapy (COT).
Methods: Twenty-four patients were randomized to NAT or COT and underwent 30 
sessions of 60 minutes time-on-task in addition to standard care. The primary outcome 
was the Fugl-Meyer Upper Extremity motor score (FM-UE). Secondary outcomes 
included: Action Research Arm Test (ARAT), grip strength, Stroke Impact Scale (SIS) 
hand domain, and upper-limb kinematics. Outcomes were assessed at baseline, and 
days 3, 90, and 180 post-training. Both groups were compared to a matched historical 
cohort (HC), which received only 30 minutes of upper limb therapy per day. 
Results: There were no significant between-group differences in FM-UE change or any 
of the secondary outcomes at any timepoint. Both high-dose groups showed greater 
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recovery on the ARAT (7.3 ±2.9 pts, p=0.011), but not the FM-UE (1.4 ±2.6 pts, p 
=0.564) when compared to the HC. 
Conclusions: Two forms of high-dose intensive upper limb therapy produced greater 
activity but not impairment improvements compared with regular care. Neuroanimation 
may offer a new enjoyable, efficient and scalable way to deliver increased upper limb 
therapy.  
Clinicaltrials.gov registration NCT02292251
Key words: stroke, motor recovery, upper limb, neuroanimation, rehabilitation
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Current neurorehabilitation approaches in the subacute period after stroke have 
been ineffective in reducing motor impairment beyond what is expected from 
spontaneous biological recovery plus standard of care1,2. Notably, however, recent 
studies in patients with chronic stroke have shown improvements with promising effect 
sizes at both the activity and impairment levels when greatly increased intensities and 
doses of regular upper limb therapy are provided3-6.
A large number of studies in non-human primates (see [8] for extensive review), 
some going back over a century, have shown that hemiparesis caused by induced focal 
lesions in motor cortical areas and/or their descending pathways can markedly improve 
with high-intensity and high-dose training regimens that specifically focus on a return to 
normal behavior, i.e., movement quality; especially when it is initiated early (within days 
and weeks of the injury)7,8. For example, in one study, monkeys began training on day 
five post-infarct and were trained on 600 pellet retrievals a day for three to four weeks9; 
full recovery of hand function was seen. In another study, monkeys were trained on food 
wells with the specific intention that they perform a normal precision grip rather than 
either of two possible compensatory strategies10.  This amount and type of upper limb 
training emphasizing movement quality (normal, non-synergistic movement patterns) of 
the affected limb is difficult to achieve in the limited amount of time available in standard 
rehabilitation, which instead by necessity incentivizes task accomplishment via 
compensation11. Furthermore, it has been reported that patients make a total of only 
about 30 upper limb task-based repetitions during a single therapy session12 – almost 
two orders of magnitude lower than in the cited monkey studies. 
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The goals of the SMARTS2 study were the following: 1) to test the feasibility and 
efficacy of upper limb therapy focused on movement quality when provided at intensities 
and doses comparable to those given in non-human primate studies, 2) to initiate high-
intensity and high-dose therapy early (<6 weeks post-stroke), and 3) to compare the 
efficacy of a new immersive and enjoyable animated experience (neuroanimation 
therapy, NAT)13 versus time-matched conventional occupational therapy (COT). We 
chose this early time window in the hope of maximizing training benefits, given the 
extensive evidence in animal models that there is increased responsiveness to training 
in the first weeks to a month after stroke14, and that most spontaneous recovery occurs 
in the first few months after stroke in humans15.
SMARTS2 was a multicenter, single-blinded, parallel randomized controlled trial 
in subacute stroke, comparing the efficacy of neuroanimation therapy versus intensive 
conventional occupational therapy. Both types of training provided high-dose, high-
intensity, movement-quality focused therapy. NAT additionally offered a gamified, 
motivating environment in which to practice these movements, which we hypothesized 
might have enhanced efficacy over more traditional forms of therapy. The hypothesis 
was that NAT would be superior to COT at reducing impairment, as measured with the 
Fugl-Meyer Upper Extremity motor score (FM-UE), and at least as good at improving 
arm activity, measured with the Action Research Arm Test (ARAT), as we expected a 
large reduction in impairment to generalize to activity. The secondary hypothesis was 
that both forms of high-intensity and high-dose therapy would be better than standard-
of-care levels of occupational therapy because there is more time to focus on 
movement quality. 
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This was a multicenter, single-blinded, parallel randomized controlled trial 
comparing the efficacy of a novel exploratory neuroanimation therapy (NAT) with time-
matched conventional occupational therapy (COT) to enhance upper limb motor 
recovery after stroke. Eligible patients within six weeks post-stroke were randomized 1:1 
to either NAT or COT using a central web-based database (Research Electronic Data 
Capture, REDCap). Randomization was blocked in groups of six and stratified 
according to baseline FM-UE score of 6-20 or 21-40. The randomization sequence was 
generated by a statistician not involved in the study and concealed from all study team 
members. 
The target therapy schedule for both groups was two daily sessions separated by 
at least an hour break, five days per week for three weeks, for a total of 30 sessions. 
Deviations from this schedule were allowed as long as all therapy sessions could be 
completed within 10 weeks post-stroke. NAT and COT were matched for active therapy 
time of 60 minutes of time-on-task per session, which was tracked by the gaming 
software in the NAT group and by stopwatch in the COT group. 
Outcome assessments were performed at four timepoints: baseline (pre-training), 
and post-training day 3 (±2 days), day 90 (±10 days), and day 180 (±10 days). All 
assessments were conducted by trained evaluators who were blinded to treatment 
allocation. Patients and caregivers were coached and given a written and verbal 
reminder not to speak to the evaluator regarding the therapy type at each assessment 
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visit. The evaluators had no contact with the participants outside of the assessment 
sessions to minimize chances of unblinding.
The trial design initially included a third arm consisting of NAT with transcranial 
direct current stimulation (tDCS). Due to slow initial recruitment, the NAT + tDCS arm 
was stopped to allow for increased recruitment in the NAT and COT groups, which was 
our primary comparison of interest. The time window for enrollment post-stroke was 
also extended from five weeks to six weeks to increase the number of eligible 
participants. 
Study Participants 
Patients were recruited from the acute stroke and inpatient rehabilitation units at 
Johns Hopkins Hospital, New York Presbyterian Hospital-Columbia, cereneo Center for 
Neurology and Rehabilitation, and their affiliated institutions. Patients were eligible for 
the study if they were 21 years old or over, had an ischemic stroke (hemispheric or 
brainstem) confirmed by CT or MRI within the previous six weeks with residual arm 
weakness (FM-UE score 6-40 pts), had no history of prior stroke with associated motor 
deficits, and were able to give informed consent and understand the tasks involved. 
Exclusion criteria included: intracranial hemorrhage, botulinum toxin injection to upper 
limb since stroke, physical or neurological condition that interfered with study 
procedures or assessment of upper limb motor function, inability to sit in a chair and 
exercise for one hour at a time, participation in another upper limb rehabilitation 
intervention study, and inability to return for all study sessions. All patients gave written 
informed consent for participation in the study. The study was approved by the 
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institutional review board at each center and registered with Clinicaltrials.gov 
(NCT02292251) prior to the start of enrollment. 
Interventions
Licensed therapists underwent both in-person and video training on the study 
interventions at each site. Materials, instructions, and documentation was standardized 
across sites, and a single therapist (L.B.) supervised training sessions.   
Neuroanimation Therapy (NAT). Participants played a custom-designed 
immersive animation-based experience: I am Dolphin  (KATA, Johns Hopkins 
University) (Figure 1). 3D movements of the paretic arm controlled the movement of a 
virtual dolphin, swimming through different ocean scenes with various task goals 
including chasing and eating fish, eluding attacks, and performing jumps. Tasks were 
designed to promote movement in all planes throughout the active ranges of motion, 
and titrated based on successful completion of progressive levels of difficulty. 
Patient’s paretic arm was unweighted using the Armeo®Power (Hocoma AG, 
Volketswil, Switzerland), an upper limb exoskeleton device. This allowed practice of 
multijoint 3D arm movements despite antigravity weakness without requiring a therapist 
to actively lift the paretic arm. The degree of unweighting provided by the exoskeleton 
was adjusted for each patient to maintain shoulder flexion to 90 degrees at rest so as to 
provide weight-support of the paretic limb throughout its full active range in all 
directions. No active assistance was given along the line of movement by the device. 
The device was integrated with a custom gaming software in a room which simulated an 
immersive oceanic environment. A large screen displayed the dolphin in his 
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environment, oceanic sounds and music were played, and the lights were dimmed for 
the entirety of each session. A licensed physical or occupational therapist was present 
throughout each session and provided verbal and tactile feedback to assure high-quality 
movements (i.e. normal non-synergistic movement patterns) and exploration of the full 
workspace.
Modified conventional occupational therapy (COT). COT targeting the upper limb 
was administered by a licensed therapist according to a written standardized protocol. 
Active COT time was matched to that of the NAT group (60 minutes per session). The 
Chedoke-McMaster Stroke Assessment Stage16 for the hand and arm was administered 
at the beginning of each week to guide interventions aligned with the specified level of 
function. Therapeutic exercises consisted of range of motion (stretching) and 
strengthening exercises of the paretic arm, and training of ADLs, such as simulated 
cooking/eating, dressing, grooming and cleaning tasks. A typical COT session would 
include 30 minutes of impairment intervention (e.g. scapular stability, weight bearing, 
active range of motion, stretching, and strengthening), and 30 minutes of activity 
training (e.g. reaching, grasping, pinching, bilateral limb coordination during functional 
activities, ADLs). Therapists were given a list of activities from which to choose but 
could add additional personalized activities that targeted the specified upper limb 
movements for the session. Functional activities were broken down into their movement 
components first and then practiced through gradual progression of complexity and 
difficulty, similar to shaping strategies employed in constraint-induced movement 
therapy. Activities were trained using either the paretic or bilateral upper limb(s) as 
appropriate for successful completion of the task. The first session of the day targeted 
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shoulder/elbow, the second session targeted wrist/hand. Therapists focused on 
movement quality during the COT sessions by preventing compensatory movements 
and discouraging use of abnormal synergies. The musical soundtrack of NAT was 
played during COT to maintain blinding if the therapy was conducted in close proximity 
to blinded evaluators. 
All therapeutic activities were documented by the therapy team, including the 
amount of assistance provided (e.g. passive mobility, active assisted mobility, weight 
bearing), any modifications to the exercise, and total time spent on each area of the 
upper limb. Participants were not explicitly instructed with regard to integrating the 
activities into the home environment.  
Clinical study outcomes 
At the baseline visit, patients underwent a comprehensive clinical evaluation that 
included: medical chart and radiological review, National Institutes of Health Stroke 
Scale (NIHSS), proprioception assessment (using distal phalanx testing, abnormal 
defined as <3/5 trials incorrect), Montreal Cognitive Assessment17, Florida Apraxia 
Battery18, star cancellation test of visuospatial neglect (presence of hemineglect 
determined by cutoff score of 4419), and Beck Depression Inventory-II20. Study 
assessments were performed at four timepoints: baseline (pre-training), and post-
training days 3 (±2 days), 90 (±10 days), and 180 (±10 days). All evaluators underwent 
video and in-person training prior to conducting study assessments and were blinded to 
patients’ treatment allocation. 
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The primary outcome measure was the change in upper limb impairment 
measured by FM-UE, from baseline to post-training day 3. The FM-UE is a widely used, 
reliable, and validated measure of motor impairment in patients with stroke21. It 
evaluates the ability to make upper limb movements in and out of synergy patterns and 
consists of 33 items graded on an ordinal scale (0-2), with a best possible score of 66. 
The minimal clinically important difference (MCID) for the FM-UE is considered to be 
approximately 10% of the maximum score, or 6.6 points21.
Secondary clinical outcome measures included changes from baseline to day 3 
post-training in: 1) ARAT, an assessment of upper limb activity limitation and dexterity 
with the MCID for the paretic arm being 12 points22 2) grip strength using a Jamar 
dynamometer (average of three trials, MCID 5kg22), and 3) the hand domain of the 
Stroke Impact Scale (SIS hand) version 2.0, a self-reported measure of hand function23. 
All measures were also assessed at 90 and 180 days post-training, to evaluate longer-
term gains. Measures of therapy compliance included number of sessions completed 
and minutes of active therapy within each session. 
Kinematics of planar reaching 
Motor control of the proximal arm was evaluated using a planar arm reaching 
task and analyzed using methods that have been previously described15 (for detailed 
information, see Supplemental Materials). 
Finger strength and individuation 
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Finger strength and individuation were evaluated using an ergonomic keyboard 
device that measures isometric forces produced by each finger24 (for detailed 
information, see Supplemental Materials). 
Statistical analysis 
Each outcome measure (FM-UE, ARAT, grip strength, SIS hand, AMD2, finger 
MVF and individuation index) was analyzed using the same framework and model 
structure. Specifically, we used a linear mixed model in which timepoint was treated as 
a categorical predictor with four levels (reference: baseline visit), therapy type was a 
categorical variable with two levels (reference: NAT), and all timepoint by therapy type 
interactions were included. Additionally, a subject-specific random intercept accounted 
for within-subject correlation across timepoints. This model structure estimates the 
mean change in outcome value from baseline to each timepoint as well as the 
difference in this change over time comparing NAT to COT groups, using all available 
subject data at each visit. Regression diagnostics were used to assess model fit, and 
two-sided Wald tests were used to assess statistical significance for group-level 
comparisons. 
We conducted a power analysis for the ability to detect a difference in treatment 
effect between NAT and COT groups. This analysis was based on a two-sample t-test 
with two-sided alpha level set at 0.05 and assumed the difference between groups in 
the change in FM-UE score would be 7 (MCID). For an effect standard deviation of 5, 
10 subjects per group yields 84% power to detect the true alternative; for an effect 
standard deviation of 7, 20 subjects per group yields 87% power. We planned to 
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randomize 24 subjects in each group, based on our observed attrition rate of 20% for 
previous longitudinal stroke studies. 
Comparison to historical cohort (HC). In exploratory analyses, we sought to 
compare FM-UE and ARAT outcomes among patients in the current study, all of whom 
received an intensive intervention, to patients who received usual clinical care. To do 
so, we used data from the EXPLICIT trial25, which was conducted in the Netherlands 
and randomized patients within 14 days of first-ever hemiparetic stroke to modified 
constraint induced movement therapy or usual care. Specifically, patients in the 
EXPLICIT usual care cohort received occupational therapy based on current Dutch 
guidelines for 30 minutes a day, five days a week for three weeks beginning within five 
weeks post-stroke. This amount of therapy approximately matches the average number 
of minutes spent on therapeutic activities for the upper limb in a typical OT session in 
the United States12. Usual care patients from the EXPLICIT trial were matched to 
patients in our intense treatment groups (entire SMARTS2 cohort) based on day post-
stroke (± 4 days) and severity (± 4 points for FM-UE and ARAT). After candidate 
matches were found, we randomly sampled a single subject to serve as the match for 
each subject in the intense treatment group. In this analysis, we computed the change 
in FM-UE and ARAT between baseline and day three post-training for patients in the 
SMARTS2 group and a similar timeframe for the matched patients in the EXPLICIT 
usual care group, and compared the average change between groups. Because there 
can be several potential matches of whom one is selected, we repeated the full analysis 
and aggregated results to account for uncertainty in the matching process. 
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Between April 2015 and October 2017, 4030 patients with ischemic stroke were 
assessed for eligibility (Figure 2). The study was stopped after 24 subjects were 
randomized due to slow recruitment. Table 1 summarizes baseline characteristics of 
patients who were randomized. The median number of days from stroke onset to 
baseline assessment was 19.0 days (IQR 12.0, 33.0) and 14.0 (IQR 12.5, 35.5) in the 
NAT and COT groups, respectively. There were no significant differences in gender, 
arm affected, proportion receiving tissue plasminogen activator or mechanical 
thrombectomy, median NIHSS score, proportion with hemineglect, proportion receiving 
selective serotonin reuptake inhibitors, or baseline FM-UE or ARAT scores. The COT 
group did have statistically worse scores on the Florida Apraxia Battery, whereas the 
NAT group had worse depression scores at baseline.
One patient in the NAT group did not receive the intervention due to 
transportation issues. Two patients withdrew from the study before the end of the 
planned intervention: one preferred to receive only standard rehabilitation, and one was 
transferred to another facility. Compliance with active therapy was high in both groups. 
Excluding the 3 patients who did not receive the intervention or withdrew before the end 
of therapy, the mean total time in active therapy was 1769 minutes for NAT (98% of 
target) and 1801 for COT (100% of target). Two patients in the NAT group required 
minimal assistance from the therapist to initiate movement in the first few sessions but 
were subsequently able to complete the training on their own. Twenty-one patients 
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completed the post-training day 3 assessment (88%), 20 completed the post-training 
day 90 assessment (83%), and 19 completed the day 180 assessment (79%). 
Clinical outcomes 
Our primary outcome was the change in FM-UE score from baseline (pre-
training) to post-training day 3. There was no significant difference between NAT and 
COT groups in our primary outcome of FM-UE changes from baseline to day 3 post-
training (difference 1.34, standard error [SE] 5.15, p=0.797), or in FM-UE changes from 
baseline to day 90 (difference -3.28, SE 5.26, p=0.316) and day 180 (difference -0.09, 
SE 5.38, p=0.132) post-training (Table 2). There was similarly no significant difference 
between NAT and COT for the change in ARAT from baseline to day 3, day 90, or day 
180 post-training (Table 2). Grip strength and SIS hand also showed no between-group 
differences in change from baseline at any timepoint (Table 2). 
Reaching kinematics 
We calculated the average squared Mahalanobis distance (AMD2) for reaching 
trajectories performed with the paretic arm at the four timepoints, compared to a 
reference population of neurologically-healthy control subjects. There were 2 patients in 
the COT group whose reaching kinematic data were excluded from analysis because 
there were too few movements in the baseline session that were suitable for inclusion in 
the analysis. An additional 2 patients were missing baseline assessments of reaching 
kinematics (1 in each group) and therefore were not included in the analysis of change 
scores from baseline. Of the remaining patients, day 90 data were missing for 2 
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subjects and day 180 data were missing for 2 patients, due to time constraints or 
withdrawal from the study. There was improvement in reach kinematics across the 
intervention period but there was no significant difference in the change in AMD2 from 
baseline between NAT and COT groups at day 3, day 90, or day 180 post-training 
(Table 2). There was a significant correlation between the AMD2 and the ARAT (p = 
0.028) but not the FM-UE (p = 0.622).
Finger strength and individuation 
Maximum voluntary force and finger individuation index were calculated for the 
more affected arm at the four timepoints as described above. 1 patient in the NAT group 
did not complete the tasks at baseline and was excluded from analysis. There were also 
data missing for 4 patients at post-training day 90 (2 in NAT and 2 in COT), and 5 
patients at post-training day 180 (2 in NAT and 3 in COT). We found no significant 
between-group difference in the change in MVC or individuation index from baseline to 
any post-training timepoint. (Table 2). 
Comparison of intensive therapy to the historical cohort (HC)
In an exploratory analysis, we compared the change in FM-UE and ARAT from 
baseline to post-training day 3 in our SMARTS2 study cohort (NAT and COT groups 
combined) to changes across a similar timeframe with usual care in a historical cohort 
from the EXPLICIT-stroke study25. Patients in SMARTS2 were matched by time post-
stroke and severity (FM-UE and ARAT) with patients from EXPLICIT. We observed a 
significant benefit in upper limb activity (ARAT difference 7.33, SE 2.88 pts, p=0.011) 
Page 47 of 72
http://mc.manuscriptcentral.com/nnr
































































but not for impairment (FM-UE difference 1.44, SE 2.57, p=0.564) with the intensive 
therapy provided in SMARTS2 compared with usual care (Figure 3). 
Adverse events 
There were a total of 55 adverse events (AEs) that occurred in 13 patients during 
the study. There were 4 serious adverse events in the COT gorup that were unrelated to 
the study procedures, (2 falls resulting hospitalization and 2 unrelated medical 
conditions). Of the 51 non-serious AEs, 23 (42%) occurred in the NAT group and 32 
(58%) occurred in the COT group. In the NAT group, 5 AEs were probably related (neck 
pain, fatigue in 3 patients, and bruising) and 6 AEs were possibly related (eye pain in 2 
patients, headache, nausea, worsened ataxia, and a fall) to study procedures. In the 
COT group, two AEs were definitely related (wrist pain in 2 sessions), 1 probably related 
(pain), and two possibly related (pain, fall) to study procedures.
DISCUSSION
In this randomized, single-blinded proof-of-concept trial we sought to test the 
idea, inspired by studies in non-human primates, that high-intensity and high-dose 
upper limb therapy focused on movement quality rather than task accomplishment, and 
delivered early after stroke, would reduce motor impairment more than usual care does. 
We tested this main idea by taking two distinct approaches. The first was administering 
high doses of conventional upper limb therapy. The second was a new immersive 
animated experience that centers on a proprietary form of animation designed to 
promote playful exploration of high quality continuous 3D arm movements13. Here we 
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found that both approaches led to similar changes in the FM-UE, ARAT, reaching 
kinematics, finger strength, and finger individuation. Looking at a historical cohort, we 
found that both approaches were superior to usual care with respect to the ARAT but 
not the FM-UE. Unfortunately, hand and planar kinematic measures were not available 
for the historical cohort. 
Conventional occupational therapy (COT) mainly emphasizes repetitive task-
oriented training (TOT)26,27, an approach predicated on practice schedules based on 
motor learning principles. Not much time is dedicated to the upper limb in regular 
therapy sessions12, which means that TOT focuses more on compensatory movements 
for task accomplishment. That said, there is nothing inherent to COT that precludes a 
switch in emphasis to movement quality, especially if therapists are given more time 
with the patient, as they were in SMARTS2. In three recent studies in patients with 
chronic stroke, large gains in both the ARAT (or other activity-level measure) and the 
FM-UE were seen when patients were provided with either five or six hours of upper 
limb therapy a day for five days/week for three, six or twelve weeks3-5. Clearly these are 
very high intensities and doses of therapy. In two of the studies4,5, the authors explicitly 
state that they wanted to make “movement practice as close to normal as possible”, and 
did so by progressing from single-joint to two-joint movements, then assembling these 
into task components and finally practicing performance of the full task. It is evident that 
they combined the more traditional neurophysiological approach, which focuses on 
movement quality, with TOT. The therapists in our study took a comparable approach in 
the COT group, as outlined in the methods section. In fact, they explicitly stated on 
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questioning that they were able to focus on movement quality precisely because they 
had more time with the patient. 
The NAT and COT groups showed comparable changes in ARAT scores. These 
changes were significantly greater than the changes seen in the historical control group 
receiving usual care over the same time period. The ARAT is a valid and responsive 
measure of upper limb activity on the ICF scale28,29 and its components have 
considerable overlap with the reach and grasp tasks in non-human primate experiments 
investigating motor recovery. Indeed, the ARAT correlates well with kinematic measures 
of reach and grasp30. 
We argue here that the changes in the ARAT in the NAT and COT groups are an 
indication of true improvement in the quality of arm and hand motor control and not just 
compensation, even though performance on items scored less than 3 (i.e., “normal”) 
can include compensatory movements. First, we know that the ARAT can show, just like 
the FM-UE, changes, as we saw here (13.4 and 14.70 points from baseline to day 3 
post-training in NAT and COT groups, respectively), that are larger earlier compared to 
later after stroke 31. That ARAT changes are greater when high-dose therapy is given 
earlier than later means suggests that they, at least in part, reflect true restitution and 
not just learned compensation. Second, if the two intervention groups were just being 
trained to compensate better than usual care, then this must be because they learned to 
compensate during the intervention. This would not be possible for the NAT group, 
however, because there was no prehension  functional reach and grasp training of any 
kind – the virtual dolphins were steered with the arm only.. Third, large improvements in 
activity measures have been seen with intense and high dose COT in patients with 
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chronic stroke5,6. These changes seem to be dose-dependent, only becoming large 
when 90 hours or more of treatment are given3-5. In contrast, 32 hours does not lead to 
large ARAT changes31. If large ARAT changes were just due to optimizing 
compensatory strategies it seems unlikely that they would not also be seen after 32 
hours of COT. Finally, here we found a significant correlation, as have others30,32, 
between improvement in the quality of arm kinematics and the ARAT. Thus, like in non-
human primates8, we conclude that intense and high-dose upper limb therapy focused 
on movement quality can at least partially restore motor control in the upper limb in the 
subacute period after stroke; it does not just train compensatory movements. 
Notably, we did not see an increase in the FM-UE, our primary outcome 
measure, beyond what was seen in the usual care historical control group. Of course, 
as we were studying subacute rather than chronic stroke, there were large changes in 
the FM-UE due to spontaneous recovery but we were not able to augment them with 
either of our interventions. It is always possible that this is a false negative result given 
the low n, but a previous study of early intense and high-dose upper limb therapy, in this 
case constraint-induced movement therapy, also reported a dissociation between the 
ARAT and the FM-UE25. 
It is possible for ARAT improvements to reflect true changes in motor control and 
yet not be detected by the FM-UE score due to differences in emphasis for the two 
scales. For example, a patient who has regained active range of movement in the 
shoulder/elbow but has persistent difficulty with out of synergy movements (e.g., unable 
to initiate shoulder flexion or abduction without bending the elbow, which would confer a 
score of “0” on these FM-UE items) may nevertheless improve on the ARAT by gaining 
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the ability to reach the top shelf through improved shoulder flexion and elbow extension. 
Another situation in which one may see a dissociation between FM-UE and ARAT 
changes is a patient who primarily regains distal dexterity, which is weighted more 
heavily on the ARAT than the FM-UE. 
The differential responsiveness of the FM-UE and the ARAT to an intervention is 
not altogether surprising. FM-UE and ARAT measure different constructs of the ICF 
model, reflecting the levels of body function and activity, respectively. In addition, the 
FM-UE scale was primarily devised to quantify post-stroke synergies over the course of 
motor recovery 33 whereas the ARAT emphasizes assessment of prehension (combined 
reach and grasp) during more functional tasks29,34. In other words, one primarily targets 
a positive sign and the other a negative sign of the upper motor neuron syndrome8. That 
being said, synergies will intrude on a functional task, especially in the absence of arm 
weight support35,36, which is why the two measures often correlate with each other37,38. 
It is unfortunate that the FM-UE has come to be considered synonymous with overall 
impairment after stroke, even though it was designed to assess mostly a single 
component of impairment, namely synergies, over strength or dexterity. This is 
problematic because thus far it seems that the positive and negative symptoms of 
stroke respond differently to interventions in the sub-acute period. In this study, we saw 
significant improvement in ARAT but not in FM-UE with our intensive movement quality-
focused training, and a similar finding was reported when extra sessions of constraint-
induced movement therapy were added in the sub-acute period in the EXPLICIT trial25.  
The divergence of ARAT and FM-UE in comparison to usual care was descriptive rather 
than statistical, due to the challenges in performing a robust statistical comparison 
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between values of different scales, the dependence between tests of each outcome, 
and the repeated matching framework that was used to compare recovery between 
groups. Nevertheless, the differences in p-values supports a divergence for FM-UE (p = 
0.564) and ARAT (p = 0.011). It is to be hoped that new kinematic measures will soon 
be developed that can distinguish arm dexterity/quality of motor control from both 
synergies and compensation during performance of 3D functional tasks39,40. This is of 
utmost importance because hemiparesis in humans appears to be both a deficit 
disorder related to damage to the corticospinal tract41,42 and a movement disorder, 
perhaps related to upregulation of the reticulospinal tract43-45. These positive and 
negative signs of hemiparesis will likely need distinct forms of intervention. 
Our findings for the NAT and COT groups are congruent with what has been 
reported in many recent neurorehabilitation studies and trials – both the novel 
intervention group and the control group show similar, and often large, treatment 
responses. This has been taken as evidence that new technological or pharmacological 
interventions do not outperform higher intensities and doses of conventional therapy or, 
by extension, usual clinical care. In a recent review of 15 neurorehabilitation trials 
conducted in the last five years it is stated: “There is no clear evidence that 
interventions tested in large multicenter stroke rehabilitation trials are superior to current 
care. Furthermore, patients benefited from both the experimental and control 
interventions at both the subacute and chronic stages”46. The crucial point being missed 
here, however, is that control interventions in clinical trials often consist of more, and 
sometimes considerably more, conventional therapy than is usually given during regular 
clinical care. This is certainly the case in our study where patients in the COT group 
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received two hours a day of therapy for five consecutive days over three weeks. 
Because of the greatly increased time available, both NAT and COT were able to 
increase the emphasis on movement quality and discourage use of compensatory 
movements. At the very least, one can safely say that there was more movement-
quality-based training than in the historical cohort. In addition, trials tend to select for 
patients with less comorbidity and fewer cognitive deficits, which allows them to receive 
higher doses of usual care. Therefore, the positive results for controls in trials do not 
imply that usual conventional care is equally efficacious to the novel intervention. 
Indeed, trials that have directly compared higher doses with usual doses of conventional 
care have found a difference between them47-49. Thus, the fact that a new approach, like 
the NAT here, is not significantly different from high doses of COT should be taken as a 
reason for optimism. This implies that the new intervention must possess an active 
ingredient that potentially could be further optimized in terms of efficacy, efficiency, cost-
effectiveness, and scalability. This situation can be considered analogous to what 
happened in the evolution of thrombectomy for acute stroke. In 2013, three trials 
showed no benefit of thrombectomy over usual care50-52. By 2015, five trials showed 
superiority for thrombectomy53. What happened? The two main reasons were choice of 
the correct technology for clot removal and a change in protocol design.
As with post-stroke thrombolysis, it is possible that we are on the cusp of a 
change in the delivery and efficacy of upper limb neurorehabilitation. In this case, the 
correct choice would be to move toward more immersive experiences to promote 
intense exploratory training with a focus on movement quality. The protocol change 
would be, as in SMARTS2, to encourage exploratory multi-joint movements outside of a 
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task context for at least two hours a day. Thus, based on the results here, we suggest 
that an alternative to just increasing the amount of time available to administer COT, is 
to devise technology-based solutions are scalable and that make it easier and more 
enjoyable to deliver higher doses and intensities of impairment-focused therapy54. It 
should also be emphasized, that even though in this small study we found no significant 
difference between COT and NAT for delivery of higher doses of intense upper limb 
therapy, it does not need to be either/or. It may turn out that the two approaches can 
complement each other. COT could be considered analogous to drills in sport, for 
example practicing backhands in tennis for an hour. NAT could be the holistic approach 
where you combine all the components into a full game. 
Compliance with therapy was high in both NAT and COT groups, reaching 98% 
and 100% of targeted time on task, respectively. Overall both interventions were safe, 
with no serious adverse events related to study procedures. There were, however, more 
adverse events in the COT group than the NAT group. Fatigue was reported more often 
in the NAT group, which therapists did not always perceive to be a negative because 
the therapy was designed to be challenging. Other side effects in the NAT group such 
as transient headache and pain have been reported previously with game-based 
interventions and are not unexpected with high intensity training55.
This study clearly has a number of limitations. First, the number of patients in this 
proof-of-concept trial was low. Indeed, we recruited only half the number of patients we 
anticipated. This is attributable both to our inclusion/exclusion criteria and the 
challenges of providing two hours of time-on-task upper limb therapy, five days a week 
beginning in the first six weeks after stroke in addition to usual care56,57. Furthermore, 
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incorporation of mechanical thrombectomy as standard of care led to fewer patients with 
severe to moderate motor deficits. Second, we were only able to begin our interventions 
after patients were discharged from in-patient acute rehabilitation at the sites in the 
United States due to the challenges of delivering high doses of therapy in addition to 
standard care in the inpatient rehabilitation setting as well as the need for short length of 
stay58; the average start time was therefore about three weeks post-stroke. From our 
previous work, we have shown that the time window of heightened neuroplasticity 
responsible for spontaneous recovery, and perhaps for enhanced training-related 
improvement that takes advantage of this heightened neuroplasticity, might be as short 
as 5 weeks15. This difficulty with our enrollment time window attests to the continuing 
challenge of conducting neurorehabilitation trials in this early time period after 
stroke46,58,59. Third, we did not track amount of upper limb activity at home during this 
study, thus are unable to quantify whether either of the training interventions influenced 
amount of limb use in the real world. Fourth, we had to use a historical usual care 
group, albeit an extensive and well-matched one25. This was necessary because we 
were not able to ask patients to enroll in a trial offering three weeks of extra care with 
the chance that they would end up in the control group that got no extra therapy but 
would nevertheless require them to make trips to the hospital for assessment. Given our 
strict time window offering the active intervention later was not an option. Another point, 
as we made above, is that in clinical trials, the control intervention is most often not 
“usual” care but an amplified and often unrealistic version of it46. Here we were fortunate 
that a cohort existed that delivered care of the upper limb that was close to what 
patients actually receive in the subacute post-stroke period. 
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Increasing the dose and intensity of upper limb rehabilitation training early after 
stroke, with focus on movement quality, led to gains beyond those seen with usual care. 
This additional improvement was achieved either by having therapists provide much 
more COT or with a novel exploratory animation-based approach with exoskeletal 
weight support. This is exciting, as it suggests that an immersive animation-based 
experience combined with weight-support might pave the way forward for providing high 
doses of upper limb rehabilitation focused on movement quality in a more efficient, 
enjoyable, and scalable way at any time post-stroke. 
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We thank the reviewers for their comments and have addressed them point-by-
point below and in the revised manuscript. 
1. The authors appear to be agreeing with my point that the divergence in 
ARAT and FM is descriptive. However, they are still keen to state 
'Nevertheless, our results support a divergence for FM-UE (p = 0.564) and 
ARAT (p = 0.011).' based on the fact that the two p-values are not 
'qualitatively similar'. I'm afraid this is not justified and this sentence should 
not remain. I agree that the authors can keep their discussion of FM and 
ARAT differences because it's interesting, but I want to remind them that 
this was not part of the study aims.
Response: We agree and have removed the sentence 'Nevertheless, our 
results support a divergence for FM-UE (p = 0.564) and ARAT (p = 
0.011).’
2. The removal of prehension addresses the last point
Response: We have removed the word “prehension” (p.19) and have 
changed it to “functional reach and grasp training”.  In the description of 
the ARAT (p.21) we have also clarified that “ARAT emphasizes 
assessment of prehension (combined reach and grasp) during more 
functional tasks.”
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Table 1. Participant characteristics at baseline 
          NAT    COT p-values
  (n=13)   (n=11)
Age in years (SD) 62.0 (10.4) 64.4 (14.0) 0.640
Gender male (%) 5 (38.5%) 6 (54.5%) 0.706
Nondominant affected 7 (53.8%) 5 (45.5%) 1.000
Received tPA (%) 10 (76.9%) 7 (63.6%) 0.793
Thrombectomy (%) 2 (15.4%) 3 (27.3%) 0.834
Days between stroke 19.0 [12.0,33.0] 14.0 [12.5,35.5] 0.663
onset and baseline 
assessment
(median [IQR])
NIHSS (median [IQR]) 6.0 [6.0,10.0] 6.0 [5.5, 9.5] 0.859
Florida Apraxia Battery 15 [15, 15] 14 [12.5, 15] 0.031
(median [IQR])
Hemineglect (%) 1 (7.7%) 1 (10.0%) 1.000
Abnormal 2 (15.4%) 5 (45.5%) 0.244
proprioception (%)
Beck Depression 17 [11,19] 5 [3,8] 0.025
(median [IQR])
Taking SSRI (%) 10 (76.9%) 4 (36.4%) 0.111
Baseline FM-UE 23.8 (12.1) 22.2 (8.7) 0.562
(median [IQR])
Baseline ARAT 10.0 [3.0, 33.0] 9.0 [3.0, 21.5] 0.640
(median [IQR])
NAT = neuroanimation therapy. COT = conventional occupational therapy. tPA = tissue 
plasminogen activator. NIHSS = National Institutes of Health Stroke Scale. Florida 
Apraxia Battery scores range 0-15 with a lower score indicating worse apraxia. 
SSRI=selective serotonin reuptake inhibitor. FM-UE=Fugl-Meyer Upper Extremity motor 
score. ARAT=Action Research Arm Test 
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Baseline to day 3 Baseline to day 90 Baseline to day 180
NAT COT Difference (SE)   p NAT COT Difference p NAT COT Difference p 
FM-UE 12.5 13.4 0.9 (3.7) 0.797 18.2 14.4 -3.8 (3.8) 0.316 19.6 13.8 -5.8 (3.8) 0.132
ARAT 13.4 14.7 1.3 (5.1) 0.795 19.8 16.5 -3.3 (5.3) 0.532 21.7 21.6 -0.1 (5.4) 0.986
Grip strength 8.57 2.63 -5.93 (6.27) 0.344 12.39 8.23 -4.16 (6.38) 0.515 16.36 7.26 -9.10 (6.51) 0.162
(lbs) 
SIS hand 21.8 14.0 -7.8 (11.1) 0.480 36.8 20.1 -16.7 (11.3) 0.139 42.3 29.9 -12.4 (11.5) 0.282
Reaching -30.87 -26.67 4.20 (14.11) 0.766 -39.73 -50.12 -10.39 (14.75) 0.482 -41.42 -48.84 -7.42 (15.03) 0.622
AMD2
Finger MVF 0.14 0.20 0.06 (0.13) 0.647 0.26 0.33 0.07 (0.14) 0.632 0.24 0.24 0.00 (0.14) 0.992
(N)
Finger 0.22 0.19 -0.03 (0.12) 0.780 0.31 0.31 0.00 (0.13) 0.999 0.36 0.31 -0.05 (0.14) 0.717
Individuation
Table 2. Results of mixed model estimates of changes from baseline to post-training days 3, 90, and 180.  
There were no significant differences between NAT and OT groups in any of the primary or secondary outcome measures. 
Abbreviations: NAT=neuroanimation therapy; COT=conventional occupational therapy; SE=standard error; p=p-value; FM-
UE=Fugl-Meyer Upper Extremity motor assessment; ARAT=Action Research Arm Test; SIS hand=Stroke Impact Scale v.2 
hand domain; AMD2=average squared Mahalanobis distance; MVF=maximum voluntary force. 
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Figure 1.  Participants in the neuroanimation therapy group played the MindPod Dolphin game while their 
arm was unweighted by the Armeo®Power exoskeleton device. 
722x541mm (72 x 72 DPI) 
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Assessed for eligibility (n= 4030) 
) 
Excluded  (n= 4006) 
♦			Not meeting inclusion criteria (n= 
3991) 
♦			Declined to participate (n= 15) 
 
Analyzed at Day 3 (n=11) 
 
Analyzed at Day 90 (n=11) 
 
Analyzed at Day 180 (n=11) 
 
Lost to follow-up at Day 3 (n=0) 
Lost to follow-up at Day 90 (n=0) 
Lost to follow-up at Day 180 (n=0) 
 
•  
Allocated to NAT (n=13) 
 
♦	Discontinued intervention (n=2)	
     Lack of transportation (n=1), withdrew (n=1) 
	
Lost to follow-up at Day 3 (n=0) 
Lost to follow-up at Day 90 (n=1, withdrew) 
Lost to follow-up at Day 180 (n=1, travel) 
Allocated to COT (n=11) 
 
♦	Discontinued intervention (n=1) 
     Withdrew and transferred from facility (n=1) 
	
Analyzed at Day 3 (n=10) 
 
Analyzed at Day 90 (n=9) 
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Figure 3. Comparison between the SMARTS2 study cohort receiving intensive therapy (dotted line) and a 
historical cohort from the EXPLICIT trial receiving usual care (means represented by heavy lines, individual 
subjects by thin solid lines). The groups were matched for baseline time post-stroke and severity. A 
significant benefit in upper limb activity and dexterity (ARAT), but not for upper limb impairment (FM-UE), 
was seen with the intensive therapy provided in SMARTS2. 
480x331mm (150 x 150 DPI) 
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Supplemental Material: Comparing a novel neuroanimation experience to 
conventional therapy for high-dose, intensive upper-limb training in subacute 
stroke: The SMARTS2 randomized trial 
Extended Methods
Kinematics of planar reaching 
Patients sat at a glass-surface table with their trunk secured to a chair and their hand 
and forearm immobilized with a splint, allowing only movements of the shoulder and 
elbow. The forearm was supported using an air-sled system to create a frictionless 
environment. Patients were instructed to make straight movements with a cursor from a 
central start circle to four circular targets (1 cm radius, 8 cm distance). Hand position 
was tracked in real-time using Flock of Birds (Ascension Technology, USA) (JHU, CU) 
or trakSTAR (Ascension Technology, USA) magnetic recording system at a sampling 
rate of 130 Hz. Each trial began after the cursor was held inside the start circle for 0.5 s. 
Audiovisual feedback, a pleasant ding and a change of target color, was provided to 
movements that ended and remained inside the target with a peak velocity within the 
range of 20-40 cm/s. If movements fell outside of this velocity range, auditory feedback 
was provided indicating whether the movement was too fast or too slow. 
Hand position data were analyzed using custom routines in IGOR Pro 
(Wavemetrics, USA) and R1. Data were low-pass filtered (8 Hz Butterworth filter) and 
differentiated to yield tangential velocity and acceleration. Left arm data were spatially 
flipped across the vertical axis, which allowed for grouping of movements that were 
directed to targets requiring similar joint configurations. For each movement, we 
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identified the velocity peak as the first zero-crossing of acceleration above a velocity 
threshold of 5 cm/s. The velocity trace was scanned backwards to identify the time 
when it crossed 1 cm/s; this was marked as the movement-start time. Movement-end 
time was defined as the first point after the peak velocity when the velocity trace 
remained below 1 cm/s. The following movements were excluded from further analyses: 
those that did not reach a peak velocity of >5 cm/s, those in which the velocity remained 
>1 cm/s at the end of the trial, those in which the movement did not leave the starting 
circle. 
The reaching trajectories were analyzed using functional principal component 
analysis, as previously described (FPCA)2. This analysis compares each patient’s 
movements to those of a control group using a global, data-driven metric that is 
sensitive to changes in overall movement quality. A control group of 12 neurologically-
healthy volunteers of a similar age distribution as the stroke patients (mean age = 58.4 
years) served as a reference population for kinematic analysis. Subject-specific average 
squared Mahalanobis distances (AMD2) were computed to summarize the distribution of 
movements for each subject at each target, and then averaged across targets, for each 
timepoint; larger values of AMD2 indicate movement distributions that are more 
dissimilar from those of controls.
Finger strength and individuation 
Force transducers (FSG-15N1A, Honeywell; dynamic range 0-50N) measured 
the downward isometric force exerted at each fingertip with a sampling rate of 200 Hz. 
The data were digitized using National Instrument USB-621x and MATLAB (MathWorks, 
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Natick, MA) Data Acquisition Toolbox. Visual stimuli were presented on a computer 
monitor running custom routines written in MATLAB Psychophysics Toolbox.
 Patients were seated in front of a computer monitor and rested their hands on the 
keyboards with each finger on top of a key. Ten vertical gray bars representing the 10 
fingers were shown at the top of the screen, and another 10 vertical bars below them 
instructed the amount of force to be exerted. The required force level for each finger per 
trial was indicated by the position of a horizontal white line. 
 Maximum voluntary contraction force (MVF) and individuation were tested. 
During each MVF trial, patients were asked to press downward with one finger at a time 
with maximum strength and maintain this force level for 2 seconds. MVF was measured 
twice for each finger. In the finger individuation trials, patients were instructed to press 
only one finger at a sub-MVF force level while keeping other fingers immobile. Four 
target force levels were tested for each finger: 20%, 40%, 60%, and 80% of MVF; each 
level was repeated 4 times. On each trial, the patient was instructed to bring the 
corresponding horizontal white line up to the force target line and then maintain the 
required force level for 0.5 seconds. Strength and individuation indices were derived 
from the raw force traces recorded from the device as described previously3.
 Strength index. To obtain a measure of finger strength, we used the 95th 
percentile of the force traces produced across all sampled force data points during the 
finger-depressing period in each trial and then averaged across the two MVF trials. If 
the force achieved on one of the two trials was below 60% of that produced on the other 
trial, only the larger force was used (13.2% of trials were excluded). The overall strength 
of the hand was then calculated by averaging across all five fingers.
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 Individuation index. For each trial, we obtained the mean deviation from the 
baseline force (before GO-cue onset) of each uninstructed finger by averaging over all 
time bins (5ms/bin) over the entire force trace. A positive linear relationship between the 
mean deviation of the non-instructed fingers and the instructed finger force is captured 
by the slope of the regression line of these two variables. To represent the data in a 
more intuitive manner, we took the negative log of the slope for each of the instructed 
fingers and averaged across all fingers. A higher value of this index indicates better 
individuation.
Supplemental References
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Vienna, Austria: R Foundation for Statistical Computing; 2014.
2. Cortes JC, Goldsmith J, Harran MD, et al. A Short and Distinct Time Window for 
Recovery of Arm Motor Control Early After Stroke Revealed With a Global 
Measure of Trajectory Kinematics. Neurorehabil Neural Repair. 2017;31(6):552-
560.
3. Xu J, Ejaz N, Hertler B, et al. Separable systems for recovery of finger strength 
and control after stroke. J Neurophysiol. 2017;118(2):1151-1163.
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CONSORT 2010 checklist  Page 1 




No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title  




2a Scientific background and explanation of rationale  
2b Specific objectives or hypotheses  
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio  
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons  
Participants 4a Eligibility criteria for participants  
4b Settings and locations where the data were collected  
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
 
6b Any changes to trial outcomes after the trial commenced, with reasons  
Sample size 7a How sample size was determined  
7b When applicable, explanation of any interim analyses and stopping guidelines  
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence  




9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those  
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CONSORT 2010 checklist  Page 2 
assessing outcomes) and how 
11b If relevant, description of the similarity of interventions  
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes  
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses  
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
 
13b For each group, losses and exclusions after randomisation, together with reasons  
Recruitment 14a Dates defining the periods of recruitment and follow-up  
14b Why the trial ended or was stopped  
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group  
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 




17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence int rval) 
 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended  
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)  
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses  
Generalisability 21 Generalisability (external validity, applicability) of the trial findings  
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence  
Other information  
Registration 23 Registration number and name of trial registry  
Protocol 24 Where the full trial protocol can be accessed, if available  
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders  
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
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